Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Pulmonx to Present at the Stifel 2024 Healthcare Conference
Here's What Analysts Are Forecasting For Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter Results [Yahoo! Finance]
Pulmonx Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
Pulmonx Co. (NASDAQ: LUNG) had its price target lowered by analysts at Stifel Nicolaus from $17.00 to $16.00. They now have a "buy" rating on the stock.